相关实验视频
Updated: Jan 15, 2026
07:06
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
34.8K
NEAT1促进结核性硬化复合体中的生
Suhui Kuang1,2,3, Tinghong Liu1,2, Zhirong Wei1
1Functional Neurosurgery Department, National Children's Health Center of China, Beijing Children's Hospital, Capital Medical University, Beijing, 100045, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|October 15, 2025
概括
长非编码RNANEAT1在结核性硬化综合体 (TSC) 神经问题中起着关键作用. 在TSC模型中减少NEAT1改善了和认知功能,这表明NEAT1是治疗标.
科学领域:
- 神经科学是一个神经科学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 结核性硬化综合体 (TSC) 导致严重的神经问题,如和认知障碍,治疗选择有限.
- 表观遗传因素,特别是长非编码RNA (lncRNAs) 在TSC病变发生过程中的作用尚不清楚.
研究的目的:
- 调查 lncRNA NEAT1 在TSC相关和认知缺陷中的功能.
- 探索NEAT1在TSC相关的关键信号通路中的参与.
主要方法:
- 临床TSC组织样本的RNA测序.
- 开发和利用NEAT1操纵TSC2条件淘汰的小鼠和细胞模型.
- 在体内监测发作和行为测试 (空间学习,工作记忆).
- 信号通路,神经递质平衡和离子通道功能的细胞分析.
主要成果:
- 在TSC茎中,NEAT1具有差异性表达,并且与PI3K-AKT通路相关.
- 在TSC模型中,NEAT1的降低降低了发作频率,并改善了记忆力.
- NEAT1调节PI3K/AKT/mTOR通路,神经递质受体平衡和电流.
- NEAT1的过度表达激活了mTORC1,促进了异常的细胞增殖,并导致神经元过度兴奋.
结论:
- 在TSC的背景下,NEAT1是神经元功能和刺激性的重要调节者.
- 向NEAT1提供了一个有前途的治疗策略,用于管理TSC中的和认知功能障碍.
相关概念视频
01:24Epilepsy and Seizures: Overview
1.2K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
822
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
822